A Study of Induction Dosing With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C (CHC) Genotype 1 Infection

NCT00192647 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

896

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: PEG-IFN alfa-2a
DRUG: Ribavirin

Sponsor

Hoffmann-La Roche